TLR7 and neoplasm: This strategy has successfully boosted the activation of antigen-specific CD8+ T cells and NK cells, leading to enhanced anti-tumor effects in a murine melanoma model.853 Nanoparticles carrying TLR7/8 agonists, such as R848, show potential in enhancing antibody-dependent immunotherapy mediated by NK cells, potentially reshaping the tumor microenvironment and enhancing the effectiveness of cancer immunotherapy.854 Nanoparticles co-loaded with two Toll-like receptor (TLR) agonists demonstrate synergistic effects in promoting adaptive immune responses, functioning as a co-delivery system.